Document 0150
 DOCN  M95B0150
 TI    Inhibition of gene expression with ribozymes.
 DT    9511
 AU    Marschall P; Thomson JB; Eckstein F; Max-Planck-Institut fur
       Experimentelle Medizin, Gottingen,; Germany.
 SO    Cell Mol Neurobiol. 1994 Oct;14(5):523-38. Unique Identifier : AIDSLINE
       MED/95346988
 AB    1. Ribozymes can be designed to cleave in trans, i.e. several substrate
       molecules can be turned over by one molecule of the catalytic RNA. Only
       small molecular weight ribozymes, or small ribozymes, are discussed in
       this review with particular emphasis on the hammerhead ribozyme as this
       has been most widely used for the inhibition of gene expression by
       cleavage of mRNAs. 2. Cellular delivery of the ribozyme is of crucial
       importance for the success of inhibition of gene expression by this
       methodology. Two modes of delivery can be envisaged, endogenous and
       exogenous delivery. Of the former several variants exist, depending on
       the vector used. The latter is still in its infancy, even though
       chemical modification has rendered such ribozymes resistant against
       degradation by serum nucleases without impairment of catalytic
       efficiency. 3. Various successful applications of ribozymes for the
       inhibition of gene expression are discussed, with particular emphasis on
       HIV1 and cancer targets. These examples demonstrate the promise of this
       methodology.
 DE    Animal  Antiviral Agents/ADMINISTRATION & DOSAGE/PHARMACOLOGY  Base
       Sequence  Catalysis  Cells, Cultured  Gene Expression Regulation/*DRUG
       EFFECTS  Human  HIV-1/GENETICS  Liposomes  Molecular Sequence Data
       Neoplasms/DRUG THERAPY  Nucleic Acid Conformation  RNA,
       Antisense/PHARMACOLOGY  RNA, Catalytic/ADMINISTRATION &
       DOSAGE/*PHARMACOLOGY  RNA, Messenger/METABOLISM  Subcellular
       Fractions/METABOLISM  Support, Non-U.S. Gov't  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).